The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 .mu.g to 60 .mu.g, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.